If the industry needed another sign that preclinical-stage firms are making a comeback as hot investment prospects – last week's upsized initial public offering by Agios Therapeutics Inc., for example, met with an impressive trading debut on Wall Street – privately held Atyr Pharma Inc. delivered more promising news Monday, disclosing an oversubscribed $49 million Series D round to support work on its rare disease pipeline.